ketendoКлиническая и экспериментальная тиреоидологияClinical and experimental thyroidology1995-54722310-3787Endocrinology Research Centre10.14341/ket12818ketendo-12818Research ArticleНАУЧНЫЕ ОБЗОРЫREVIEWSЖидкий левотироксин: вопросы и ответыLiquid levothyroxine: questions and answershttps://orcid.org/0000-0003-1500-1586МоргуноваТ. Б.MorgunovaT. B.

Моргунова Татьяна Борисовна, к.м.н. 

119048, Москва, ул. Трубецкая, д. 8, стр. 2 

Tatyana B. Morgunova, MD, Cand. Sci. (Med.) 

8 Trubetskaya str., build. 2, 119048, Moscow 

tanmorgun@mail.ruhttps://orcid.org/0000-0003-0069-1692РыжковаЕ. Г.RyzhkovaE. G.

Рыжкова Екатерина Геннадьевна, аспирант 

Москва

Ekaterina G. Ryzhkova, MD, posrgraduate student 

Moscow 

e.g.ryzhkova@bk.ruhttps://orcid.org/0009-0008-0209-9979ГалкинаА. П.GalkinaA. P.

Галкина Анна Петровна 

Москва

Anna P. Galkina, MD 

Moscow 

anyagalkina01@mail.ruhttps://orcid.org/0000-0002-3026-6315ФадеевВ. В.FadeevV. V.

Фадеев Валентин Викторович, д.м.н., профессор, член-корр. РАН 

Москва

Valentin V. Fadeev, MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences 

Moscow 

walfad@mail.ruПервый МГМУ имени И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2024190520252041519Copyright © Моргунова Т.Б., Рыжкова Е.Г., Галкина А.П., Фадеев В.В., 20252025Моргунова Т.Б., Рыжкова Е.Г., Галкина А.П., Фадеев В.В.Morgunova T.B., Ryzhkova E.G., Galkina A.P., Fadeev V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cet-endojournals.ru/jour/article/view/12818

Левотироксин (L-Т4) является препаратом с узким терапевтическим диапазоном. И даже небольшое изменение дозы может привести как к недостатку, так и к его передозировке. Существующие на сегодняшний день таблетированные формы L-T4 с широким спектром дозировок обеспечивают достижение и удержание эутиреоза у многих пациентов. Вместе с тем нередко пациенты с гипотиреозом находятся в декомпенсации. На сегодняшний день в мире применяются не только таблетки, но и другие формы L-T4, в том числе гель-капсулы и жидкая форма. В представленном обзоре обсуждаются особенности фармакокинетики, преимущества и недостатки применяемых форм L-T4. Также обсуждаются факторы, влияющие на биодоступность и определяющие дозу L-T4.

Levothyroxine (L-T4) is a drug with a narrow therapeutic range. Even a small change in the dose can lead to its deficiency or overdose. Existing tablet forms of L-T4 with a wide range of dosages ensure the achievement and maintenance of euthyroidism in many patients. At the same time, patients with hypothyroidism are often decompensated. Today, not only tablets are used in the world, but also other forms of L-T4, including gel capsules and liquid form. The presented review discusses the pharmacokinetics, advantages and disadvantages of the different forms of L-T4. Factors affecting the bioavailability of L-T4 drugs are also discussed.

жидкий левотироксинабсорбция левотироксинагипотиреоззаместительная терапияпатология желудочно-кишечного трактаliquid levothyroxinelevothyroxine absorptionhypothyroidismreplacement therapygastrointestinal disordersReferencesJonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751. doi: https://doi.org/10.1089/thy.2014.0028Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751. doi: https://doi.org/10.1089/thy.2014.0028Okosieme O, Gilbert J, Abraham P, et al. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clin Endocrinol (Oxf ). 2016;84(6):799-808. doi: https://doi.org/10.1111/cen.12824Okosieme O, Gilbert J, Abraham P, et al. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clin Endocrinol (Oxf ). 2016;84(6):799-808. doi: https://doi.org/10.1111/cen.12824Safer DJ. Overprescribed Medications for US Adults: Four Major Examples. J Clin Med Res. 2019;11(9):617-622. doi: https://doi.org/10.14740/jocmr3906Safer DJ. Overprescribed Medications for US Adults: Four Major Examples. J Clin Med Res. 2019;11(9):617-622. doi: https://doi.org/10.14740/jocmr3906NHS. Prescription Cost Analysis—England 2017 2018 [cited 2019 March, 19]. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/prescription-costanalysisengland-2017NHS. Prescription Cost Analysis—England 2017 2018 [cited 2019 March, 19]. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/prescription-costanalysisengland-2017Janett-Pellegri C, Wildisen L, Feller M, et al. Prevalence and factors associated with chronic use of levothyroxine: A cohort study. PLoS One. 2021;16(12):e0261160. doi: https://doi.org/10.1371/journal.pone.0261160Janett-Pellegri C, Wildisen L, Feller M, et al. Prevalence and factors associated with chronic use of levothyroxine: A cohort study. PLoS One. 2021;16(12):e0261160. doi: https://doi.org/10.1371/journal.pone.0261160Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526-34. doi: https://doi.org/10.1001/archinte.160.4.526Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526-34. doi: https://doi.org/10.1001/archinte.160.4.526Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med. 2014;174(1):32-9. doi: https://doi.org/10.1001/jamainternmed.2013.11312Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med. 2014;174(1):32-9. doi: https://doi.org/10.1001/jamainternmed.2013.11312Yavuz DG, Yazıcı D, Keskin L, et al. Out-of-Reference Range Thyroid-Stimulating Hormone Levels in Levothyroxine-Treated Primary Hypothyroid Patients: A Multicenter Observational Study. Front Endocrinol (Lausanne). 2017;8:215. doi: https://doi.org/10.3389/fendo.2017.00215Yavuz DG, Yazıcı D, Keskin L, et al. Out-of-Reference Range Thyroid-Stimulating Hormone Levels in LevothyroxineTreated Primary Hypothyroid Patients: A Multicenter Observational Study. Front Endocrinol (Lausanne). 2017;8:215. doi: https://doi.org/10.3389/fendo.2017.00215Molewijk E, Fliers E, Dreijerink K, et al. Quality of life, daily functioning, and symptoms in hypothyroid patients on thyroid replacement therapy: A Dutch survey. J Clin Transl Endocrinol. 2024;35:100330. doi: https://doi.org/10.1016/j.jcte.2024.100330Molewijk E, Fliers E, Dreijerink K, et al. Quality of life, daily functioning, and symptoms in hypothyroid patients on thyroid replacement therapy: A Dutch survey. J Clin Transl Endocrinol. 2024;35:100330. doi: https://doi.org/10.1016/j.jcte.2024.100330Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137(11):904-14. doi: https://doi.org/10.7326/0003-4819-137-11-200212030-00011Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137(11):904-14. doi: https://doi.org/10.7326/0003-4819-137-11-200212030-00011Paul TL, Kerrigan J, Kelly AM, et al. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA. 1988;259(21):3137-41. doi: https://doi.org/10.1001/jama.1988.03720210027023Paul TL, Kerrigan J, Kelly AM, et al. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA. 1988;259(21):3137-41. doi: https://doi.org/10.1001/jama.1988.03720210027023Thayakaran R, Adderley NJ, Sainsbury C, et al. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ. 2019;366:l4892. doi: https://doi.org/10.1136/bmj.l4892Thayakaran R, Adderley NJ, Sainsbury C, et al. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ. 2019;366:l4892. doi: https://doi.org/10.1136/bmj.l4892Somwaru LL, Arnold AM, Joshi N, Fried LP, Cappola AR. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab. 2009. doi: https://doi.org/10.1210/jc.2008-1696Somwaru LL, Arnold AM, Joshi N, Fried LP, Cappola AR. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab. 2009. doi: https://doi.org/10.1210/jc.2008-1696Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal Malabsorption of Thyroxine. Endocr Rev. 2019;40(1):118-136. doi: https://doi.org/10.1210/er.2018-00168Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal Malabsorption of Thyroxine. Endocr Rev. 2019;40(1):118-136. doi: https://doi.org/10.1210/er.2018-00168Castellana M, Castellana C, Giovanella L, Trimboli P. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? Endocrine. 2020;67(2):281-290. doi: https://doi.org/10.1007/s12020-019-02185-4Castellana M, Castellana C, Giovanella L, Trimboli P. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? Endocrine. 2020;67(2):281-290. doi: https://doi.org/10.1007/s12020-019-02185-4McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, Concomitant Medications, and Diet as Factors Affecting Levothyroxine Therapy: Results of the CONTROL Surveillance Project. Drugs R D. 2016;16(1):53-68. doi: https://doi.org/10.1007/s40268-015-0116-6McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, Concomitant Medications, and Diet as Factors Affecting Levothyroxine Therapy: Results of the CONTROL Surveillance Project. Drugs R D. 2016;16(1):53-68. doi: https://doi.org/10.1007/s40268-015-0116-6Benvenga S, Papi G, Antonelli A. Refractory Hypothyroidism Due to Improper Storage of Levothyroxine Tablets. Front Endocrinol (Lausanne). 2017;8:155. doi: https://doi.org/10.3389/fendo.2017.00155Benvenga S, Papi G, Antonelli A. Refractory Hypothyroidism Due to Improper Storage of Levothyroxine Tablets. Front Endocrinol (Lausanne). 2017;8:155. doi: https://doi.org/10.3389/fendo.2017.00155Мануйлова Ю.А., Моргунова Т.Б., Фадеев В.В. Причины неэффективности заместительной терапии первичного гипотиреоза. // Клиническая и экспериментальная тиреоидология. — 2019. — Т. 15. — № 1. — С. 12-18. doi: https://doi.org/10.14341/ket10163Manuylova YuA, Morgunova TB, Fadeyev VV. Causes of treatment failure in primary hypothyroidism. Clinical and experimental thyroidology. 2019;15(1):12-18. (In Russ.) doi: https://doi.org/10.14341/ket10163Bornikowska K, Gietka-Czernel M, Raczkiewicz D, et al. Improvements in Quality of Life and Thyroid Parameters in Hypothyroid Patients on Ethanol-Free Formula of Liquid Levothyroxine Therapy in Comparison to Tablet LT4 Form: An Observational Study. J Clin Med. 2021;10(22):5233. doi: https://doi.org/10.3390/jcm10225233Bornikowska K, Gietka-Czernel M, Raczkiewicz D, et al. Improvements in Quality of Life and Thyroid Parameters in Hypothyroid Patients on Ethanol-Free Formula of Liquid Levothyroxine Therapy in Comparison to Tablet LT4 Form: An Observational Study. J Clin Med. 2021;10(22):5233. doi: https://doi.org/10.3390/jcm10225233Seng Yue C, Scarsi C, Bettazzi E, et al. Proton Pump Inhibitors Do Not Affect the Bioavailability of a Novel Liquid Formulation of Levothyroxine. Endocr Pract. 2024;30(6):513-520. doi: https://doi.org/10.1016/j.eprac.2024.03.388Seng Yue C, Scarsi C, Bettazzi E, et al. Proton Pump Inhibitors Do Not Affect the Bioavailability of a Novel Liquid Formulation of Levothyroxine. Endocr Pract. 2024;30(6):513-520. doi: https://doi.org/10.1016/j.eprac.2024.03.388Yannovits N, Zintzaras E, Pouli A, et al. A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2006;31(2):73-8. doi: https://doi.org/10.1007/BF03191122Yannovits N, Zintzaras E, Pouli A, et al. A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2006;31(2):73-8. doi: https://doi.org/10.1007/BF03191122Bernareggi A, Grata E, Pinorini MT, Conti A. Oral liquid formulation of levothyroxine is stable in breakfast beverages and may improve thyroid patient compliance. Pharmaceutics. 2013;5(4):621-33. doi: https://doi.org/10.3390/pharmaceutics5040621Bernareggi A, Grata E, Pinorini MT, Conti A. Oral liquid formulation of levothyroxine is stable in breakfast beverages and may improve thyroid patient compliance. Pharmaceutics. 2013;5(4):621-33. doi: https://doi.org/10.3390/pharmaceutics5040621Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012;62(12):631-6. doi: https://doi.org/10.1055/s-0032-1329951Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012;62(12):631-6. doi: https://doi.org/10.1055/s-0032-1329951Cappelli C, Pirola I, Daffini L, et al. A Double-Blind Placebo-Controlled Trial of Liquid Thyroxine Ingested at Breakfast: Results of the TICO Study. Thyroid. 2016;26(2):197-202. doi: https://doi.org/10.1089/thy.2015.0422Cappelli C, Pirola I, Daffini L, et al. A Double-Blind Placebo-Controlled Trial of Liquid Thyroxine Ingested at Breakfast: Results of the TICO Study. Thyroid. 2016;26(2):197-202. doi: https://doi.org/10.1089/thy.2015.0422Cappelli C, Pirola I, Daffini L, Gandossi E, Agosti B, Castellano M. Thyroid hormonal profile in elderly patients treated with two different levothyroxine formulations: A single institute survey. Eur Geriatr Med. 2014;5(6):382-385. doi: https://doi.org/10.1016/j.eurger.2014.09.006Cappelli C, Pirola I, Daffini L, Gandossi E, Agosti B, Castellano M. Thyroid hormonal profile in elderly patients treated with two different levothyroxine formulations: A single institute survey. Eur Geriatr Med. 2014;5(6):382-385. doi: https://doi.org/10.1016/j.eurger.2014.09.006Negro R, Valcavi R, Agrimi D, Toulis KA. Levothyroxine liquid solution versus tablet for replacement treatment in hypothyroid patients. Endocr Pract. 2014;20(9):901-6. doi: https://doi.org/10.4158/EP13378.ORNegro R, Valcavi R, Agrimi D, Toulis KA. Levothyroxine liquid solution versus tablet for replacement treatment in hypothyroid patients. Endocr Pract. 2014;20(9):901-6. doi: https://doi.org/10.4158/EP13378.ORMarkantes GK, Dimitropoulos K, Mamali I, et al. Therapeutic Equivalence of a New Preparation of Liquid Levothyroxine with Tablets in Patients with Overt Primary Hypothyroidism. Eur Thyroid J. 2021;10(1):59-64. doi: https://doi.org/10.1159/000508216. Erratum in: Eur Thyroid J. 2021;10(1):100. doi: https://doi.org/10.1159/000509965Markantes GK, Dimitropoulos K, Mamali I, et al. Therapeutic Equivalence of a New Preparation of Liquid Levothyroxine with Tablets in Patients with Overt Primary Hypothyroidism. Eur Thyroid J. 2021;10(1):59-64. doi: https://doi.org/10.1159/000508216. Erratum in: Eur Thyroid J. 2021;10(1):100. doi: https://doi.org/10.1159/000509965Benvenga S, Di Bari F, Vita R. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017;56(1):138-145. doi: https://doi.org/10.1007/s12020-017-1244-2Benvenga S, Di Bari F, Vita R. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017;56(1):138-145. doi: https://doi.org/10.1007/s12020-017-1244-2Virili C, Giovanella L, Fallahi P, et al. Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2018;9:10. doi: https://doi.org/10.3389/fendo.2018.00010Virili C, Giovanella L, Fallahi P, et al. Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2018;9:10. doi: https://doi.org/10.3389/fendo.2018.00010Guglielmi R, Grimaldi F, Negro R, et al. Shift from Levothyroxine Tablets to Liquid Formulation at Breakfast Improves Quality of Life of Hypothyroid Patients. Endocr Metab Immune Disord Drug Targets. 2018;18(3):235-240. doi: 10.2174/1871530318666180125155348.Guglielmi R, Grimaldi F, Negro R, et al. Shift from Levothyroxine Tablets to Liquid Formulation at Breakfast Improves Quality of Life of Hypothyroid Patients. Endocr Metab Immune Disord Drug Targets. 2018;18(3):235-240. doi: 10.2174/1871530318666180125155348.

The authors declare that there are no conflicts of interest present.